[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure

TENAX THERAPEUTICS, INC. amendment reports that Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton each disclose ownership tied to 202,480 warrants to purchase common stock.

Rhea-AI Filing Summary

TENAX THERAPEUTICS, INC. amendment reports that Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton each disclose ownership tied to 202,480 warrants to purchase common stock. The filing states those Warrants represent 0.78% of the class and contain a 9.9% beneficial ownership cap.

The Reporting Persons list a principal business address of 444 Madison Ave, Floor 41, New York, NY 10022 and the issuer address as 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517. Signatures are dated 05/15/2026.

Insights

Corporate Governance Specialist

Disclosure shows warrant-based stake with a capped exercise limit.

The filing documents that the Reporting Persons' position consists of 202,480 Warrants and states a 9.9% beneficial ownership limit that may prevent exercise beyond that threshold. This is an ownership-format disclosure under Schedule 13G/A.

Implications depend on holder decisions; the cap is an explicit constraint on exercise rights and is a governance/contractual limiter investors can verify in future filings.

Capital Markets Analyst

Warrants create potential future dilution but are contractually capped.

The position is expressed as 202,480 Warrants equal to 0.78% of outstanding common stock per the cover page. The disclosure clarifies these are Warrants, not currently issued common shares.

Cash‑flow treatment and exercise timing are not described here; subsequent filings would show any actual exercises or purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:14 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

TENAX THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Lind Global Fund II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 202,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 202,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

202,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.78 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 warrants to purchase shares of common stock (the "Warrants"). Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Lind Global Partners II LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 202,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 202,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

202,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.78 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 202,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 202,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

202,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.78 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of 202,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TENAX THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, 27517
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund II LP, a Delaware limited partnership; o Lind Global Partners II LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP. Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund II LP

Signature:	By: Lind Global Partners II LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	05/15/2026

Lind Global Partners II LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	05/15/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	05/15/2026